Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume is slowing. ETF news and IND submission news will send this to .50 cents in 30 days or less. It's been there before!!!
Maybe Celgene makes a large investment and joins the PMCB Board this weekend, or maybe a 100% acquisition. Burn these penny stock shorts. Wow
Yeah I remember the nutrition bars and the Cinnechol and the acne product
a few years ago this moved from a few ennies to over 60 cents in a matter of a few weeks.
Celgene will buy PMCB. Just a matter of time.
Nice article regarding CIAB and Ascites Fluid accumulation in pancreatic cancer patients.
https://coloncancernewstoday.com/2015/04/13/pancreatic-cancer-drug-works-against-accumulation-of-malignant-ascites-fluid-in-colon-cancer-patients/
Big Player Sigma-Aldrich is carrying CIAB kits from Austrianova on its website. I have attached the link.
http://www.sigmaaldrich.com/technical-documents/articles/biology/cell-in-a-box.html
Over 40 peer-reviewed journal articles on the CIAB technology. Sigma-Aldrich is working with Austrianova to bring CIAB to a wider audience.
Von Hoff helping Pharmacyte
He is the best in the business and helped Celgene. See article below.
TGen Physician-In-Chief Dr. Daniel Von Hoff inducted today into Joshua Lederberg Society
Dr. Von Hoff is honored for advancing FDA approved treatment benefiting pancreatic cancer patients
PHOENIX, Ariz. - Feb. 13, 2014 - Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute (TGen), will be inducted today into the Joshua Lederberg Society for his work in developing the drug Abraxane for advanced pancreatic cancer patients.
The Lederberg Society is named for the late Dr. Joshua Lederberg, a Nobel Prize laureate and leader in bacterial genetics whose expertise and guidance played a key role in the birth of Celgene, a global biopharmaceutical company that produces Abraxane.
Dr. Von Hoff, who is considered among the nation's leading authorities on pancreatic cancer, will present a talk during his induction ceremony at 1 p.m. ET today at Celgene headquarters in Summit, N.J. This is the 7th induction ceremony of the Lederberg Society, which annually honors no more than two new members whose work has changed the practice of medicine.
"Dr. Von Hoff's life long achievements in pancreatic cancer treatment and research are truly remarkable, but even more remarkable is his commitment to the patients who benefit from his tireless efforts on their behalf," said Dr. Jeffrey Trent, TGen President and Research Director. "I can think of no one more deserving of this award than Dr. Von Hoff."
Dr. Von Hoff was the principal investigator of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), a multi-year international study involving 861 patients, at 151 community and academic centers in 11 nations in North America, Europe and Australia.
The study, whose findings were published Oct. 31 in the prestigious New England Journal of Medicine, found that Abraxane (nab-paclitaxel), when combined with the previous standard therapy, gemcitabine, significantly improved overall survival, progression-free survival, and drug response rates for patients with advanced pancreatic cancer. As a result of the study, the FDA on Sept. 6 approved Abraxane as a front-line therapy for such patients. In December, the European Commission also granted its approval.
"This is a new standard for treatment of metastatic pancreatic cancer that could become the backbone for other new treatment regimens," said Dr. Von Hoff at the time of the FDA approval. "The fact that Abraxane plus gemcitabine demonstrated an overall survival benefit is a significant step forward in offering new hope for our patients."
Abraxane wraps traditional chemotherapy, paclitaxel, in near-nano sized shells of albumin, a protein that the tumor could recognize as food. Once inside the tumor, the Abraxane may act like a "Trojan Horse" to release chemotherapy and kill the cancer cells.
Dr. Von Hoff also was the principal investigator for the first clinical trial of gemcitabine, the first therapy to show improvement in survival for patients with pancreatic cancer. The FDA approved gemcitabine in 1996.
The pancreas is a glandular organ behind the stomach that secretes enzymes to help digestion, and produces hormones, including insulin, which helps regulate blood-sugar metabolism.
# # #
About TGen
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.
I thought you'd like this:
http://www.forbes.com/sites/nicolefisher/2015/04/22/are-ma-replacing-rd-in-pharma/#7340a032cb57
Are M&A Replacing R&D In Pharma? - Forbes
Thought you might be interested in this: As more new drugs are bred in little biotechs, executives at giant firms are decamping to startups.
http://for.tn/1Yol2F5?xid=for_em_sh
Key here is that Big Pharma is going to gobble up these start ups like Pharmacyte.
shorts need to cover. Trump rally is done, which was largely a short covering rally. PMs turn.
Bidding War "Yes"
Von Hoff is a giant in pancreatic cancer and is helping PMCB.
Von Hoff was instrumental in helping Celgene, the Company that purchased Abraxis Bioscience for $2.9 Billion!!!!
Abraxis owner Pat Soon-Shiong invented Abraxane. The combination of Abraxane and Gemcitabine increased survival rate by 1.8 months in trials managed by Von Hoff.
PMCB has shown that its CIAB can beat the above therapy considerably. So, PMCB should be valued at at least 3 billion or more. Just saying!!
https://www.google.com/amp/www.forbes.com/sites/matthewherper/2013/01/22/celgenes-abraxane-extends-life-by-1-8-months-in-advanced-pancreatic-cancer/?client=safari
Bullish Flag or pennant position has formed. End day on High coming.
Celgene and Juno deal spells good things for PMCB potentially.
See article:
http://www.smallcapnetwork.com/Celgene-May-Want-to-Take-Notice-of-Pharmacyte-Biotech-Too-CELG-JNJ-LLY-PCYC-PMCB-JUNO/s/via/1789/article/view/p/mid/1/id/587/
Von Hoff is all the credibility that FDA needs to know that PMCB is the real deal!
Von Hoff is all the credibility that FDA needs to know that PMCB is the real deal!
NNLX, Nanologix, has developed fast diagnostic tests that identify bacteria and infectious diseases. Cheap cultured-based tests that can detect live cells vs dead cells, and can help with antibiotic sensitivity. Recent peer reviewed journal piece was rated as one of the most exciting new technologies. The speed of the tests are the fastest available. GBS, MRSA, Listeria, TB, etc.
The stock is up from 3 cents to 17 cents in the last 2 weeks.
acquisition or investment from Celegene must be coming. Maybe a 5% position will be announced publicly by Celegene.
Large volume up day. Maybe the journal article is getting investor interest. I hope a press release is coming. Good job Brett.
Bret has done a great job. I have held for over 10 years here. I hope they can eventually disclose the partnerships that are currently under NDAs. Sales and news catalyst will help throw some exposure on this company. Inexpensive robust technology should be well-received versus the less timely expensive PCR based tests.
Big Pharma and big Corporate buy up emerging tech all the time. Who u crappin!
Big Pharma buy out coming.
Cel gene will buy PMCB. Their will be a bidding war. CIAB is a delivery platform. These bigger PHarma companies can gain leverage over their pipeline and their competitors pipelines by controlling the best delivery platform that PMCB has. PMCB will be trading above $20 in 12 months time and $5 in the next 30 days. Frosr and newmixer, good luck on your shorts, but the short squeeze and launch are imminent.
New institutional investor, Feltz Wealthplan, Inc
Von Hoff has helped Celgene get drugs approved. Von Hoff may be facilitating the merger of Celgene and PMCB. Let's hope.
Definition from FDA:
Orphan drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication or if it demonstrates superior safety, efficacy, or a major contribution to patient care versus another drug of its type previously granted the designation for the same indication, as well as with potential tax credits for clinical research costs, the potential to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.
NNLX has products to detect bacteria and viral. Check out nanologix.com. Has plenty of successes but difficulty breaking through to procurement decision makers. Only a matter of time.
Sell out to large corporation. Engage an investment banker and sell it. Get private equity investors involved. Auction. Big corporate will treat it as prepaid R&D. The sales process will bring the needed exposure and a sense of urgency.
NNLX has ability to test potential Ebola patients. Needed. FYI .
Institutional investors report their stock holdings to the SEC on June 30. I hope NVLX has some new investors.
paL to be acquired maybe
PAL was top of list as of May 31, for reduction in shorted stock for the latest two weeks. The shorts are covering. But there was still 8 mil shares short. Stock price will move up!
Nvlx will get funded by Celegene or some other major pharma! I am looking forward to June 30 to see if Train Babcock has increased its stake in NVLX. also expect new institutional investors.
It's called Investor Relations at NYSE listed companies. You need to get your story out. You need to achieve fair valuation, especially if you need to raise capital to fund clinical trials and rapid growth.
Petro, is Bret B. considering attracting a new Board of Directors that could help break down the barriers to selling Nano's superior product offering? What about John Kasich who use to be on Invacare BOD. How about doing a deal with Thermo Fisher or BDK.
Eom June we will find out what additional Institutional Investors filed reports with the SEC regarding purchases of NVLX!
Information is on Bloomberg.
NVLX has new institutional investor. 13F filed by Train Babcock a Advisors, with 475 mil assets under mgt!!
It's in their 13F filing which is filed each qtr. data is available if you have access to company SEC filings.